Journal
JOURNAL OF CLINICAL MEDICINE
Volume 10, Issue 21, Pages -Publisher
MDPI
DOI: 10.3390/jcm10214909
Keywords
nuclear medicine; therapeutics; molecular imaging
Categories
Ask authors/readers for more resources
Besides PSMA, there are other potential targets for prostate cancer theranostics in nuclear medicine, such as GRPR and androgen receptor, which may have greater potential in treating early-stage and low-grade prostate cancer. Theranostics in nuclear medicine will continue to develop, with promising molecules like radiolabeled fibroblast activation protein inhibitors requiring specific studies to assess their interest in prostate cancer.
Background: Prostate-specific membrane antigen (PSMA) is not sufficiently overexpressed in a small proportion of prostate cancer (PCa) patients, who require other strategies for imaging and/or treatment. We reviewed potential targets other than PSMA for PCa theranostics in nuclear medicine that have already been tested in humans. Methods: We performed a systematic web search in the PubMed and Cochrane databases, with no time restrictions by pooling terms ( prostate cancer , prostatic neoplasms ) and ( radioligand , radiotracer ). Included articles were clinical studies. The results were synthetized by the target type. Results: We included 38 studies on six different targets: gastrin-releasing peptide receptors (GRPRs) (n = 23), androgen receptor (n = 11), somatostatin receptors (n = 6), urokinase plasminogen activator surface receptor (n = 4), fibroblast activation protein (n = 2 studies) and integrin receptors (n = 1). GRPRs, the most studied target, has a lower expression in high-grade PCa, CRPC and bone metastases. Its use might be of higher interest in treating earlier stages of PCa or low-grade PCa. Radiolabeled fibroblast activation protein inhibitors were the most recent and promising molecules, but specific studies reporting their interest in PCa are needed. Conclusion: Theranostics in nuclear medicine will continue to develop in the future, especially for PCa patients. Targets other than PSMA exist and deserve to be promoted.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available